A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

NCT04836663 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer

Interventions

DRUG: TQ-B3525 tablet

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.